相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors
Rosa M. Alvarez et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
Gillian Moore et al.
CANCERS (2021)
Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
Xiangqian Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma (vol 11, e10058, 2019)
Sofie Mohlin et al.
EMBO MOLECULAR MEDICINE (2020)
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
Sean P. Kennedy et al.
ONCOGENE (2020)
Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer
Tom Malone et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds
Ewgenij Proschak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Conformational Control of Macrocycles by Remote Structural Modification
Solomon D. Appavoo et al.
CHEMICAL REVIEWS (2019)
Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts
Xiaodong Ma et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Binding Affinity via Docking: Fact and Fiction
Tatu Pantsar et al.
MOLECULES (2018)
PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
Aziz Ur Rehman Aziz et al.
BIOMOLECULES (2018)
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Xiuning Le et al.
CANCER DISCOVERY (2016)
Characterization of INCB053914, a novel pan-PIM kinase inhibitor
Niu Shin et al.
CANCER RESEARCH (2015)
PIM kinase (and Akt) biology and signaling in tumors
Noel A. Warfel et al.
PHARMACOLOGY & THERAPEUTICS (2015)
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways
Koremu Meja et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Rodrigo Dienstmann et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The PIM Family of Serine/Threonine Kinases in Cancer
Maja Narlik-Grassow et al.
MEDICINAL RESEARCH REVIEWS (2014)
PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
Esperanza Martin-Sanchez et al.
PLOS ONE (2014)
A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas
Jason M. Foulks et al.
NEOPLASIA (2014)
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1
Chuanbing Zang et al.
CANCER LETTERS (2013)
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design
Hengmiao Cheng et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition
Carmen Blanco-Aparicio et al.
CANCER LETTERS (2011)
4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
Kevin K-C. Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
Hengmiao Cheng et al.
MEDCHEMCOMM (2010)
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Gerlincle Wernig et al.
BLOOD (2008)
Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates Bad to block Bad-mediated apoptosis in human pancreatic cancer cell lines
Ying-Yi Li et al.
CANCER RESEARCH (2006)
Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL
A Macdonald et al.
BMC CELL BIOLOGY (2006)
Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002
MD Jacobs et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
KT Kim et al.
BLOOD (2005)
分享论文
